Gradalis

We are a late-stage biopharmaceutical company focused on the development and commercialization of novel personalized therapeutics to treat cancer.  We are developing Vigil™, our proprietary immunotherapy platform in multiple advanced cancer indications with the lead program for the treatment of patients with advanced ovarian cancer.